Stock Screener App

Gratuito -

6.55

2.67% -0.18

Kala Bio Inc. (KALA)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Kala Bio Inc. Borsa (KALA) Ultime notizie

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance

NatWest Group (LON:NWG) Reaches New 12-Month High at $281.60 - Defense World

Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?

Zacks Investment Research

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance

KALA Stock Quote Price and Forecast - CNN

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

GlobeNewswire Inc.

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference - GlobeNewswire

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Kala Pharmaceuticals Announces Name Change to KALA BIO - Yahoo Finance

Kala Pharmaceuticals' KPI-012: Novel Orphan Drug Therapy For PCED - Seeking Alpha

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for ... - GlobeNewswire

Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor - GlobeNewswire

Kala Pharmaceuticals shares soar after FDA approves trial for drug to treat PCED - CBS News

Gauging the skin resident Leishmania parasites through a loop mediated isothermal amplification (LAMP) assay in post ... - Nature.com

Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight - GlobeNewswire

Kala Pharmaceuticals Inc (NASDAQ: KALA) Executes a Sale Agreement That Will Yield a Positive Cash Flow Into ... - BP Journal

Alcon buys Kala expanding eye disease portfolio - FiercePharma

Kala Pharmaceuticals Inc (NASDAQ: KALA) Recently Issued an Update on Its Drug Approval by the FDA - BP Journal

Kala acquires regenerative biotherapy developer Combangio - Pharmaceutical Technology

Pharmaceutical Technology

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the ... - GlobeNewswire

Sub-Committee of SSWC & MA approves 24 proposals for setting up new industrial enterprises - himachal headlines

himachal headlines

Hope in the Wake of Recent Failures in Huntington’s Disease - BioSpace

Kala Pharma: Eye Treatment Specialist With Much To Prove May Have Just The Product (KALA) - Seeking Alpha

Kala Pharmaceuticals' Eysuvis Can Be A Rock Star In The Dry Eye Market (NASDAQ:KALA) - Seeking Alpha

Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved (NASDAQ:KALA) - Seeking Alpha

Why Kala Pharmaceuticals Stock Sank Today - The Motley Fool

The Motley Fool

Assessing the combined effects of household type and insecticide effectiveness for kala-azar vector control using ... - Parasites & Vectors

Parasites & Vectors

Himachal Pradesh Government - Himachal Pradesh Government

Himachal Pradesh Government

Kala Pharmaceuticals Announces the Launch of INVELTYS™ and the Hiring of a Specialty Ophthalmology Sales ... - BioSpace

Rajeev Shah, Portfolio Manager and Managing Director of RA Capital Management - Solid Biosciences

Solid Biosciences

KALA BIO (KALA) Stock Price, News & Analysis - MarketBeat

$77.56

0.77%

$149.40

1.20%

$29.98

1.11%

$172.85

1.06%

$365.81

2.87%

$90.61

2.55%

Apri su Yahoo | Apri su Google | Aperto in Finviz